Sanofi Receives FDA Approval of Soliqua 100/33, for the Treatment of Adults with Type 2 Diabetes - First Injectable Once-Daily Combination of Basal Insulin and GLP-1 Receptor Agonist Approved in U.S. - Pari

Sanofi Receives FDA Approval of Soliqua 100/33, for the

Treatment of Adults with Type 2 Diabetes

- First Injectable Once-Daily Combination of Basal Insulin and GLP-1 Receptor Agonist Approved in

Paris, France November 21, 2016 Sanofi announced today that the U.S. Food and Drug Administration

(FDA) approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units

daily) or lixisenatide*.

Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients. In an insulin intensification study, Soliqua 100/33 showed better HbA1c (average blood sugar over time)

lowering versus Lantus with a majority of the 736 patients (55% vs. 30%) achieving the American Diabetes Association target of less than 7% at 30 weeks. Patients treated with Soliqua 100/33 experienced similar rates of documented (less than or equal

to 70 mg/dL) hypoglycemia compared to Lantus-treated patients. The most frequently reported adverse events included hypoglycemia, as well as nausea (10%), nasopharyngitis (7%), diarrhea (7%) and upper respiratory tract infection (5%).1

Soliqua 100/33 will be delivered in a single pre-filled pen

for once-daily dosing covering 15 to 60 Units of insulin glargine 100 Units/mL and 5 to 20 mcg of lixisenatide using SoloStar technology, the most frequently used disposable insulin injection pen platform in the world.2 Soliqua 100/33 will be

available in U.S. retail pharmacies in January 2017.

Sanofi continues to be a pioneer in developing diabetes therapies and in bringing forward

new treatment options for the approximately 50 percent of patients whose blood sugar levels remain uncontrolled on daily basal insulin. Soliqua 100/33 is an alternate new approach that can help adults living with type 2 diabetes

uncontrolled on basal insulin or lixisenatide to reach their treatment goal, said Elias Zerhouni, M.D., President, Global R&D, Sanofi.

combination was submitted for regulatory review in a total of 10 markets, including the EU, where the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the marketing

authorization of the product on November 11, 2016. It has not yet been approved for use by any health authority outside the U.S.

What is SOLIQUATM 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL?

an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise in people who are not

controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide.

Safety Information for SOLIQUATM 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL

What is the most important information I should know about SOLIQUA 100/33?

Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed.

SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be life-threatening.

Before using SOLIQUA 100/33, tell your doctor if you have had:

These medical problems may make you more likely to get pancreatitis. Stop taking SOLIQUA 100/33 and call your healthcare

provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.

Who should not use SOLIQUA 100/33?

100/33 if you are having an episode of low blood sugar (hypoglycemia) or if you are allergic to insulin glargine, lixisenatide, or any of the other ingredients in SOLIQUA 100/33.

Tell your healthcare provider about all your medical conditions, including if you:

your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIQUA 100/33

may affect the way some medicines work

How should I use SOLIQUA 100/33?

SOLIQUA 100/33 may cause serious side effects, including:

The most common side effects of SOLIQUA 100/33 may include:

Nausea and diarrhea usually happen more often when you start using SOLIQUA 100/33.

Please click here for full Prescribing Information for SOLIQUA 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL:

http://products.sanofi.us/Soliqua100-33/Soliqua100-33.pdf.

About Sanofi Diabetes & Cardiovascular

Diabetes and cardiovascular disease affect millions of people worldwide, with many managing the complex challenges of both. Building on our portfolio

evolution, heritage and expertise, Sanofi has a focused business unit dedicated to delivering innovative, value-based medicines and integrated solutions in these therapeutic areas. We are committed to a collaborative approach that involves strategic

alliances with professional and patient associations, research institutions and leaders in healthcare and other industries, with the goal of advancing scientific knowledge, driving the convergence of science and technology, helping to improve

outcomes and inspiring an evolution in care.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi is organized into five

global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements

release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates

regarding the marketing and other potential of Soliqua, or regarding potential future revenues from Soliqua. Forward-looking statements are generally identified by the words expects , anticipates , believes ,

intends , estimates , plans and similar expressions. Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that

forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from

those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect

the availability or commercial potential of Soliqua, the absence of guarantee that Soliqua will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data

relating to Soliqua, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and

volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding

Forward-Looking Statements in Sanofi s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to

update or revise any forward-looking information or statements.